Both compounds ameliorated intestinal barrier dysfunction and colonic inflammation in colitis mice, mediated through AMPK activation and regulation of the SIRT1/NF-κB pathway, whereas dihydro resveratrol (DHR), another microbial metabolite of RES, showed no significant effects either in vivo or in vitro. Here, NFKB1 is linked to colitis.